In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Millennium Gets a Product, and Capabilities

Executive Summary

Millennium Pharmaceuticals Inc.'s acquisition of Cor Therapeutics Inc. brings the technology integrator a marketed product (Integrilin), the infrastructure that supports it, and, in Vaughn Kailian, Cor's CEO who will now head Millennium's commercial operations, a highly capable biopharmaceutical executive. The firms says their research programs are complementary--even if they don't appear to be at first glance.
Advertisement

Related Content

Millennium: The Risks of Forward Integration
Millennium: The Risks of Forward Integration
Terra Infirma: Pharma Dealmaking 2001
Biotech's Holiday Shopping Spree--Buy, Buy, Buy
Biotech's Holiday Shopping Spree--Buy, Buy, Buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel